Charles River Laboratories International (CRL) Net Income towards Common Stockholders (2016 - 2025)
Charles River Laboratories International has reported Net Income towards Common Stockholders over the past 16 years, most recently at -$276.6 million for Q4 2025.
- For Q4 2025, Net Income towards Common Stockholders fell 28.21% year-over-year to -$276.6 million; the TTM value through Dec 2025 reached -$144.3 million, down 1501.75%, while the annual FY2025 figure was -$144.3 million, 1501.75% down from the prior year.
- Net Income towards Common Stockholders for Q4 2025 was -$276.6 million at Charles River Laboratories International, down from $54.4 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $189.1 million in Q4 2022 and troughed at -$276.6 million in Q4 2025.
- A 5-year average of $61.6 million and a median of $90.0 million in 2021 define the central range for Net Income towards Common Stockholders.
- Biggest five-year swings in Net Income towards Common Stockholders: surged 48.94% in 2022 and later crashed 215.3% in 2024.
- Year by year, Net Income towards Common Stockholders stood at $139.8 million in 2021, then skyrocketed by 35.24% to $189.1 million in 2022, then decreased by 1.07% to $187.1 million in 2023, then crashed by 215.3% to -$215.7 million in 2024, then decreased by 28.21% to -$276.6 million in 2025.
- Business Quant data shows Net Income towards Common Stockholders for CRL at -$276.6 million in Q4 2025, $54.4 million in Q3 2025, and $52.3 million in Q2 2025.